Kamada Ltd (IL:KMDA) has released an update.
Kamada Ltd., a leading biopharmaceutical company, will unveil its financial outcomes for Q1 2024 on May 8 before the U.S. markets open and will host a conference call to discuss the results. The company, known for its specialty in plasma-derived products, has a significant commercial presence distributing FDA-approved biopharmaceuticals globally and is also progressing with an investigational inhaled AAT treatment in late-stage clinical trials.
For further insights into IL:KMDA stock, check out TipRanks’ Stock Analysis page.
